Kiromic Biopharma Acquires InSilico Solutions

VeriSIM Life Acquires Molomics Biotech

May 11, 2022

Biotechnology

VeriSIM Life, an AI-driven virtual drug development company based in San Francisco, has acquired Molomics Biotech SL, a Barcelona-based AI-enabled drug discovery firm. The acquisition integrates Molomics' AI + Human Collective Intelligence discovery technology into VeriSIM's BIOiSIM platform to accelerate and improve success rates in drug discovery, including work on Parkinson's disease.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Kite (a Gilead Company) to Acquire Interius BioTherapeutics

August 21, 2025

Biotechnology

Kite, a Gilead company, entered into a definitive agreement to acquire Interius BioTherapeutics for $350 million in cash. The acquisition is intended to advance Kite’s in vivo CAR T-cell therapy platform by incorporating Interius’s integrating in vivo platform, delivered via a single intravenous infusion.

Moderna Acquires OriCiro Genomics K.K. for $85 Million

January 5, 2023

Biotechnology

Moderna has entered into a definitive agreement to acquire OriCiro Genomics K.K. for $85 million. The deal is intended to add cell-free DNA synthesis and amplification technologies that complement Moderna’s mRNA manufacturing expertise and accelerate its R&D.

QuartzBio (Precision for Medicine) Acquires SolveBio

January 24, 2023

Cloud & SaaS

QuartzBio, a business unit of Precision for Medicine, has acquired SolveBio and integrated its enterprise biomarker and genomic data management platform into QuartzBio’s end-to-end SaaS suite. The acquisition expands QuartzBio’s capabilities for sample inventory, biomarker data management and enterprise-level visibility to better serve pharmaceutical and biotech clients in clinical research and development.

Illumina Acquires SomaLogic from Standard BioTools to Expand Proteomics and Multiomics

January 30, 2026

Healthcare Services

Illumina, Inc. completed the acquisition of SomaLogic to expand its data-driven proteomics and multiomics capabilities. The deal is valued at $350 million in upfront cash paid at closing, plus up to $75 million in near-term performance-based milestones and performance-based royalties, with SomaLogic products and services expected to be supported during integration into Illumina’s roadmap.